APLS Insider Trading
Insider Ownership Percentage: 6.80%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $8,088,904.82
Apellis Pharmaceuticals Insider Trading History Chart
This chart shows the insider buying and selling history at Apellis Pharmaceuticals by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Apellis Pharmaceuticals Share Price & Price History
Current Price: $19.61
Price Change: ▲ Price Increase of +0.91 (4.87%)
As of 04/9/2025 05:00 PM ET
Apellis Pharmaceuticals Insider Trading History
SEC Filings (Institutional Ownership Changes) for Apellis Pharmaceuticals (NASDAQ:APLS)
96.29% of Apellis Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Institutional Buying and Selling by Quarter
This chart shows the instiutional buying and selling at APLS by year and by quarter.
Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
Apellis Pharmaceuticals Institutional Trading History
Data available starting January 2016
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Read More on Apellis Pharmaceuticals
Today's Range
Now: $19.61
52 Week Range
Now: $19.61
Volume
2,905,357 shs
Average Volume
2,117,595 shs
Market Capitalization
$2.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.85
Who are the company insiders with the largest holdings of Apellis Pharmaceuticals?
Apellis Pharmaceuticals' top insider investors include:
- Pascal Deschatelets (Insider)
- Cedric Francois (CEO)
- Alec Machiels (Director)
- A Sinclair Dunlop (Director)
- David O Watson (General Counsel)
- Timothy Eugene Sullivan (CFO)
- Adam J Townsend (Insider)
- Nur Nicholson (Insider)
- Mark Jeffrey Delong (Insider)
- Jeffrey Eisele (Insider)
- Lukas Scheibler (Insider)
- Caroline Baumal (Insider)
- James George Chopas (CAO)
- Karen Lewis (Insider)
Learn More about top insider investors at Apellis Pharmaceuticals.
Who are the major institutional investors of Apellis Pharmaceuticals?
Which institutional investors are selling Apellis Pharmaceuticals stock?
Within the last quarter, APLS stock was sold by these institutional investors:
- Rhumbline Advisers
In the last year, company insiders that have sold Apellis Pharmaceuticals company stock include:
- Pascal Deschatelets (Insider)
- Cedric Francois (CEO)
- Alec Machiels (Director)
- A Sinclair Dunlop (Director)
- David O Watson (General Counsel)
- Timothy Eugene Sullivan (CFO)
- Adam J Townsend (Insider)
- Nur Nicholson (Insider)
- Mark Jeffrey Delong (Insider)
- Jeffrey Eisele (Insider)
Learn More investors selling Apellis Pharmaceuticals stock.
Which institutional investors are buying Apellis Pharmaceuticals stock?
During the previous quarter, APLS stock was purchased by institutional investors including:
- GAMMA Investing LLC